The Johns Hopkins University

Other

Peter John McDonnell

Justin Scot Hanes

Samuel K Lai

Yasin A Khan

Renata T Kashiwabuchi

Ashley Behrens

Hai-Quan Mao

Qingguo Xu

Shuming Zhang

Fabiana Kimie Kashiwabuchi

David E Huang

Norman B Javitt

Jonathan C Javitt

Kunal S Parikh

Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or TOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

Sustained delivery of therapeutic agents to an eye compartment

Ophthalmic suture materials made from biocompatible and biodegradable polymers with high tensile strength for use in drug delivery, methods of making them, and method of using them for ocular surgery and repair have been developed. The suture materials are made from a combination of a biodegradable, biocompatible polymer and a hydrophilic biocompatible polymer. In a preferred embodiment the suture materials are made from a poly(hydroxyl acid) such as poly(1-lactic acid) and a polyalkylene oxide such as poly(ethylene glycol) or a polyalkylene oxide block copolymer. The sutures entrap (e.g., encapsulate) one or more therapeutic, prophylactic or diagnostic agents and provide prolonged release over a period of at least a week, preferably a month.

Methods of making drug loaded microfiber sutures for ophthalmic application

Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

Ophthalmic suture materials made from biocompatible and biodegradable polymers with high tensile strength for use in drug delivery, methods of making them, and method of using them for ocular surgery and repair have been developed. The suture materials are made from a combination of a biodegradable, biocompatible polymer and a hydrophilic biocompatible polymer. In a preferred embodiment the suture materials are made from a poly(hydroxyl acid) such as poly(l-lactic acid) and a polyalkylene oxide such as poly(ethylene glycol) or a polyalkylene oxide block copolymer. The sutures entrap (e.g., encapsulate) one or more therapeutic, prophylactic or diagnostic agents and provide prolonged release over a period of at least a week, preferably a month.

Drug loaded microfiber sutures for ophthalmic application

Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

Noncontact apparatus and method for preforming laser thermal keratoplasty capable of scanning of treatment areas with shapes that reduce regression. The apparatus includes laser sources, a projection optical system, observation system, and control system The projection system uses two steering mirrors to control laser beam position on the cornea. This projection system enables precise control of the area of corneal heat shrinkage using relatively low-powered lasers, such as diode lasers. Desired changes in corneal refractive power are produced by selected patterns of photothermal shrinkage of corneal collagen tissue. The selected patterns are arrangements of oblong shapes that are preferably tapered at the ends of the long axis. The oblong shape and tapering distribute tension in the cornea over a wider area of collagen shrinkage and improve the stability of refractive correction. The long axes of the oblong treatment areas are preferably oriented radially for hyperopia correction and circumferentially for astigmatism correction.

Apparatus and method for performing laser thermal keratoplasty with

A topical composition comprising an amount of a carbonic anhydrase inhibitor and an amount of .beta.-cyclodextrin derivative effective in increasing the bioavailability of the carbonic anhydrase inhibitor when coadministered topically to the eye.

Growing community of inventors

Baltimore, MD, United States of America

Peter John McDonnell